top of page

Tue, 28 Jun



Oxford Biodynamics plc HY results webinar

Jon Burrows, CEO presents the HY results which are released on 28 June and updates on current performance.

Registration is closed
See other events
Oxford Biodynamics plc HY results webinar
Oxford Biodynamics plc HY results webinar

Time & Location

28 Jun 2022, 12:30


About the event

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. In February 2022 it launched the Checkpoint Inhibitor Response Test (CiRT) which predicts the immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments. The  Company’s products are based on its proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

Share this event

bottom of page